{"id":"NCT04518306","sponsor":"George Medicines PTY Limited","briefTitle":"Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension","officialTitle":"Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Placebo for the Treatment of Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-06-14","primaryCompletion":"2023-09-19","completion":"2023-10-18","firstPosted":"2020-08-19","resultsPosted":"2025-06-03","lastUpdate":"2025-06-03"},"enrollment":755,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg","otherNames":[]},{"type":"DRUG","name":"Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Triple ¼ (GMRx2)","type":"EXPERIMENTAL"},{"label":"Triple ½ (GMRx2)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to placebo.","primaryOutcome":{"measure":"Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4","timeFrame":"Randomization to Week 4","effectByArm":[{"arm":"Triple ¼ (GMRx2)","deltaMin":-9.6,"sd":1},{"arm":"Triple ½ (GMRx2)","deltaMin":-10.4,"sd":1.33},{"arm":"Placebo","deltaMin":-2.2,"sd":1.16}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":47,"countries":["United States","Australia","Nigeria","Sri Lanka","United Kingdom"]},"refs":{"pmids":["39217570"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":113},"commonTop":["Headache","Blood uric acid increased","Dizziness","Lipids abnormal","Blood sodium increased"]}}